ImmunityBio ANKTIVA approved in UAE across two indications

The Emirates Drug Establishment granted Marketing Authorization for ANKTIVA in UAE, expanding its global footprint to 34 countries, marking the 5th regulatory jurisdiction to authorize the therapy. The approval is significant for being the first worldwide to cover the full spectrum of BCG-unresponsive bladder cancer, reflecting continued regulatory momentum for the company's therapeutic portfolio.